Conference Menu

Download Brochure
Hotel & Travel
Sponsor & Exhibit
Request Brochure
Exhibit Contract

Media Partners:



Genetic Engineering News


Genomeweb Logo 

Future Science

Science AAAS


The Scientist 

Targeting Mitochondrial Dysfunction & Toxicity Conference - Overview

Mitochondrial failure and/or dysfunction has been identified as an important factor in diseases ranging from neurodegenerative conditions (ALS, Alzheimer’s, Parkinson’s Disease), epilepsy and autism, to diseases of the cardiovascular system, liver, and kidney, as well as cancer and diabetes. The broad impact of mitochondria in so many diseases makes them prime targets for therapeutics.

Since medications for many diseases cause unwanted toxicity to the mitochondria, it is extremely critical for drug discovery and development researchers to be able to predict and prevent this serious side effect for their compounds. This conference will present the latest research in new targeting pathways, novel therapeutics, and new breakthroughs in the understanding of mitochondrial function, as well as methods to decrease or eliminate mitochondrial toxicity when developing therapeutics.

Preliminary Agenda


Novel Genetic Tools to Study Mitochondria-to-Nucleus Cross Talk: Identification of Nuclear Targets Involved in Drug Sensitivity and Toxicity

Keshav K. Singh, Ph.D., Joy and Bill Harbert Endowed Chair; Professor, Genetics, Pathology and Environmental Health; Founding Editor-in-Chief, Mitochondrion Journal; Director, Cancer Genetics Program, UAB Comprehensive Cancer Center


Next-Generation Mitochondrial Medicine Platform: Integrated Bioenergetic Phenotyping in Oncology as a Case Study

Anne Diers, Ph.D., Program Leader, Cancer Biology, Berg

Overview of Mitochondrial Studies in the United States Air Force Research Laboratory: Toxic Impacts of Air Force Materials and Deployment Stresses

Richard Chapleau, Ph.D., Lead Biochemist, Molecular Bioeffects Branch, Bioeffects Division, Human Effectiveness Directorate, 711th Human Performance, Henry M. Jackson Foundation for the Advancement of Military Medicine

A New Answer to an Old Problem: The Energization of Brain Mitochondria Is Regulated by Cytosolic Calcium via the "Mitochondrial Gas Pedal" and Does Not Require the Mitochondrial Ca Uptake via the Ca Uniporter

Frank Gellerich, Ph.D., Head, Bioenergetic Laboratory, Neurological University Hospital, Otto-von Guericke-University Magdeburg


Adaptive Metabolic Targeting of BPM 31510 for the Treatment of Cancer

Michael Kiebish, Ph.D., Director, Integrative Systems Medicine, Diagnostics, Berg

Correcting Abnormal Mitochondrial Dynamics and Mitophagy in Neurodegenerative Diseases

Daria Mochly-Rosen, Ph.D., Professor, Chemical and Systems Biology, Medicine, Stanford University


A Systematic Assessment of Mitochondrial Function Identified Novel Signatures for Drug-Induced Mitochondrial Disruption in Cells

Padma K. Narayanan, Ph.D., Department of Comparative Biology and Safety Sciences, Amgen

Screening Small Molecules for Mitofunctional Effects: Implications for Mitochondrial Therapeutics and Mitotoxins

Gino Cortopassi, Ph.D., Professor, Molecular Biosciences, UC Davis; CEO, Ixchel PharmA

If you have questions, please contact: 
Elizabeth J. Lamb
Senior Conference Director
Cambridge Healthtech Institute
Ph:  781-247-6259

By Series:
By Region:

& Course Catalog

CHI Catalog 

Short Course DVDs